SGO Winter Meeting | Conference

High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma

January 31st 2025

High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

January 31st 2025

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

January 31st 2025

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

January 30th 2025

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

January 30th 2025

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

January 29th 2024

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

January 26th 2024

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Dr Smith on the Predictive Value of CA-125 KELIM Score for Outcomes With HIPEC in Ovarian Cancer

January 26th 2024

Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.

CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery

January 26th 2024

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies

January 26th 2024

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

January 26th 2024

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Frontline Maintenance Requires Careful Consideration in Advanced Ovarian Cancer

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.

February 1st 2022

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.